Our focus is on prevention of venous thrombosis and pulmonary embolism in high risk cancer patients with our drug candidate ISQ950AN, containing our patented Isoquercetin formulation.
Quercis Pharma AG is leveraging its novel antithrombotic platform to deliver innovative, safe, and broadly accessible treatments to patients with potentially life-threatening conditions.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.